- Home
- ICMB vs STTK Comparison
ICMB vs STTK Comparison
Compare ICMB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICMB
- STTK
- Stock Information
- Founded
- ICMB 2012
- STTK 2016
- Country
- ICMB United States
- STTK United States
- Employees
- ICMB N/A
- STTK N/A
- Industry
- ICMB Finance: Consumer Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ICMB Finance
- STTK Health Care
- Exchange
- ICMB Nasdaq
- STTK Nasdaq
- Market Cap
- ICMB 41.1M
- STTK 37.6M
- IPO Year
- ICMB N/A
- STTK 2020
- Fundamental
- Price
- ICMB $2.85
- STTK $0.96
- Analyst Decision
- ICMB
- STTK Hold
- Analyst Count
- ICMB 0
- STTK 4
- Target Price
- ICMB N/A
- STTK $3.00
- AVG Volume (30 Days)
- ICMB 36.7K
- STTK 116.5K
- Earning Date
- ICMB 05-13-2025
- STTK 07-31-2025
- Dividend Yield
- ICMB 16.78%
- STTK N/A
- EPS Growth
- ICMB N/A
- STTK N/A
- EPS
- ICMB 0.82
- STTK N/A
- Revenue
- ICMB $20,996,189.00
- STTK $4,606,000.00
- Revenue This Year
- ICMB N/A
- STTK N/A
- Revenue Next Year
- ICMB N/A
- STTK N/A
- P/E Ratio
- ICMB $3.42
- STTK N/A
- Revenue Growth
- ICMB N/A
- STTK 69.65
- 52 Week Low
- ICMB $2.46
- STTK $0.69
- 52 Week High
- ICMB $3.47
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- ICMB 52.61
- STTK 44.24
- Support Level
- ICMB $2.75
- STTK $0.95
- Resistance Level
- ICMB $3.00
- STTK $1.24
- Average True Range (ATR)
- ICMB 0.09
- STTK 0.08
- MACD
- ICMB 0.01
- STTK -0.02
- Stochastic Oscillator
- ICMB 58.82
- STTK 5.05
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.